Endo Pharmaceuticals Holdings (ENDP) Tops Q4 EPS by 7c, Reaffirms Outlook
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Price: $0.29 --0%
Financial Fact:
Selling, general and administrative: 159.9M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Selling, general and administrative: 159.9M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q4 EPS of $1.62, $0.07 better than the analyst estimate of $1.55. Revenue for the quarter came in at $801.1 million versus the consensus estimate of $807.98 million. Endo Pharmaceuticals Holdings reaffirmed FY2013 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- S&P 500 may pull back before midterms, but Citi says buy the dip
- UBS Upgrades Apollo Tyres (APTY:IN) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
